The regulatory reform plan made by the Chinese State Food and Drug Administration (SFDA) was examined by Ropes & Gray Advisor, Katherine Wang in a recent publication on mondaq.com. The “Reform Plan” aims to improve efficiency of technical reviews and regulatory approvals for new drugs and generics, improve quality control for clinical studies and advance the development of pediatric drugs. One way the SFDA plans to carry out these policies is by revising the Drug Regulation Rules to match the international norm. To read Wang’s full article, click here.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.